{
  "submission_file": "src/content/submissions/2026-02/2026-02-28T18-08-36Z_keytruda-becomes-first-immunotherapy-to-extend-sur.json",
  "article_title": "Keytruda Becomes First Immunotherapy to Extend Survival in Platinum-Resistant Ovarian Cancer",
  "fetched_at": "2026-02-28T18:16:07.407Z",
  "sources": [
    {
      "url": "https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-pembrolizumab-paclitaxel-platinum-resistant-epithelial-ovarian-fallopian-tube-or",
      "file": "source-0.html",
      "status_code": 200,
      "content_type": "text/html; charset=UTF-8",
      "content_length": 37073,
      "sha256": "2e99d70778346ad0eb07cac74f5f04f1053c9ecbc5842902356b462dc275f61e",
      "error": null,
      "fetched_at": "2026-02-28T18:16:05.421Z",
      "redirected_domain": null
    },
    {
      "url": "https://www.merck.com/news/keytruda-pembrolizumab-plus-paclitaxel-with-or-without-bevacizumab-significantly-improved-key-secondary-endpoint-of-overall-survival-os-versus-paclitaxel-with-or-without-bevacizumab-in-patie/",
      "file": "source-1.html",
      "status_code": 200,
      "content_type": "text/html; charset=UTF-8",
      "content_length": 182419,
      "sha256": "61774080976011504da21100d5677d87d97b88e6088f86b6787d8d818c3409ca",
      "error": null,
      "fetched_at": "2026-02-28T18:16:05.439Z",
      "redirected_domain": null
    },
    {
      "url": "https://www.cancernetwork.com/view/pembrolizumab-combo-significantly-improves-pfs-os-in-recurrent-proc",
      "file": "source-2.html",
      "status_code": 200,
      "content_type": "text/html; charset=utf-8",
      "content_length": 418399,
      "sha256": "1bce40ea9e67a374c991ce69066bd4b7d3bd0c9850716039ad523a3a9b952d7e",
      "error": null,
      "fetched_at": "2026-02-28T18:16:05.440Z",
      "redirected_domain": null
    }
  ]
}